Business Context and Reporting Period
This Form 8-K filing by Quince Therapeutics, Inc. (QNCX) reports a significant corporate governance event. The report date is January 30, 2026, with the document signed on February 2, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On January 30, 2026, the entire Board of Directors resigned effective immediately. The departing directors are:
- Rajiv Patni
- Luca Benatti
- Margi McLoughlin
- Una Ryan
- June Bray
The Company explicitly states that these resignations were not the result of any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies are detailed beyond the immediate impact of the board resignations.
Investor Verification Checklist
- Verify the composition of the new Board of Directors and the timeline for appointments.
- Confirm whether the resignations were part of a planned transition or triggered by undisclosed external factors.
- Review subsequent filings for any changes in executive leadership or strategic direction.
- Check for any related proxy statements or press releases explaining the rationale for the complete board turnover.